✦ LIBER ✦

A proof-of-principle study of epigenetic therapy with hydralazine and magnesium valproate plus doxorubicin cyclophosphamide as neoadjuvant therapy for locally advanced breast cancer

✍ Scribed by Claudia Arce; Carlos Perez-Plasencia; Aurora Gonzalez-Fierro; Erik de la Cruz-Hernandez; Alma Revilla-Vazquez; Alma Chavez-Blanco; Catalina Trejo-Becerril; Enrique Perez-Cardenas; Lucia Taja-Chayeb; Enrique Bargallo; Patricia Villarreal; Teresa Ramirez; Teresa Vela; Myrna Candelaria; Maria F Camargo; Elizabeth Robles; Alfonso Dueñas-Gonzalez

Book ID: 115011183
Publisher: BioMed Central
Year: 2007
Tongue: English
Weight: 165 KB
Volume: 7
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-7-s1-a23

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Concurrent Bevacizumab with a Sequential

Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2− Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group

✍ Priya Rastogi; Marc E. Buyse; Sandra M. Swain; Samuel A. Jacobs; André Robidoux; 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 570 KB

Tamoxifen versus tamoxifen plus doxorubi

Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401)

✍ Shien, Tadahiko; Iwata, Hiroji; Aogi, Kenjiro; Fukutomi, Takashi; Inoue, Kenichi 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 307 KB

A combination therapy with mitomycin c,

A combination therapy with mitomycin c, etoposide, doxifluridine and medroxyprogesterone acetate as second line therapy for advanced breast cancer refractory to combination chemotherapy of cyclophosphamide, doxorubicin and 5 fluorouracil

✍ Katsumasa Kuroi; Akihiko Osaki; Hiroyuki Kawami; Shigeru Murakami; Tetsuya Toge 📂 Article 📅 1997 🏛 Springer Japan 🌐 English ⚖ 374 KB

Phase II study of liposome-encapsulated

Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification

✍ Saracchini, S.; Foltran, L.; Tuccia, F.; Bassini, A.; Sulfaro, S.; Micheli, E.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 548 KB

Repetitive high-dose therapy with cyclop

Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study

✍ Prince, H M; Rischin, D; Toner, G C; Seymour, J F; Blakey, D; Gates, P; Eerhard, 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 78 KB

Seven-Year Follow-Up Assessment of Cardi

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

✍ Zibelman, M.; Goldstein, L.J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB